{"id":40197,"date":"2026-11-02T10:00:00","date_gmt":"2026-11-02T09:00:00","guid":{"rendered":"https:\/\/ggba.swiss\/?p=40197"},"modified":"2026-11-02T08:56:29","modified_gmt":"2026-11-02T07:56:29","slug":"biodelphis-therapeutics-polasight-et-swiss-soil-obtiennent-chacune-un-pret-tech-seed-de-chf-100000","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/biodelphis-therapeutics-polasight-et-swiss-soil-obtiennent-chacune-un-pret-tech-seed-de-chf-100000\/","title":{"rendered":"Biodelphis Therapeutics, PolaSight et Swiss Soil obtiennent chacune un pr\u00eat Tech Seed de CHF 100&rsquo;000"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">La <a href=\"https:\/\/www.fondation-fit.ch\/fr\/\">Fondation pour l&rsquo;Innovation et la Technologie<\/a> (FIT) a accord\u00e9 un pr\u00eat Tech Seed de CHF 100&rsquo;000 \u00e0 chacune de trois start-ups : <a href=\"https:\/\/www.biodelphis.com\/\">Biodelphis Therapeutics<\/a>, <a href=\"https:\/\/www.polasight.com\/\">PolaSight<\/a> et <a href=\"https:\/\/www.swisssoil.com\/\">Swiss Soil<\/a>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Biodelphis Therapeutics : un traitement cibl\u00e9 contre l&rsquo;ost\u00e9oporose<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Dans l&rsquo;ost\u00e9oporose, les cellules qui d\u00e9gradent l&rsquo;os prennent le dessus et les os deviennent fragiles. Bloquer une prot\u00e9ine de ces cellules, la cathepsine K, peut ralentir le processus, mais cinq m\u00e9dicaments de ce type ont \u00e9t\u00e9 abandonn\u00e9s en cours de d\u00e9veloppement, dont un en derni\u00e8re phase d&rsquo;essais cliniques en raison d&rsquo;un risque accru d&rsquo;AVC, car ils agissaient dans tout l&rsquo;organisme. <a href=\"https:\/\/www.biodelphis.com\/\">Biodelphis Therapeutics<\/a>, une spin-off de l&rsquo;EPFL, fixe une petite mol\u00e9cule inhibitrice \u00e0 un anticorps qui l&rsquo;achemine uniquement vers les cellules qui d\u00e9gradent l&rsquo;os. La start-up applique la m\u00eame approche au cancer du poumon, et ses premiers candidats m\u00e9dicaments ont montr\u00e9 leur efficacit\u00e9 lors d&rsquo;\u00e9tudes sur l&rsquo;animal. Le pr\u00eat l&rsquo;aidera \u00e0 d\u00e9montrer que son traitement contre l&rsquo;ost\u00e9oporose n&rsquo;augmente pas le risque d&rsquo;AVC et \u00e0 mener une premi\u00e8re \u00e9tude sur le comportement du m\u00e9dicament dans l&rsquo;organisme, des \u00e9tapes qui pr\u00e9c\u00e8dent les \u00e9tudes requises avant les premiers essais chez l&rsquo;humain.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">PolaSight : un diagnostic plus rapide pendant la chirurgie du cancer<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.polasight.com\/\">PolaSight<\/a>, une spin-off de l&rsquo;Universit\u00e9 de Berne, a d\u00e9velopp\u00e9 PolaOne, un scanner qui aide les pathologistes \u00e0 analyser les \u00e9chantillons de tissu pr\u00e9lev\u00e9s pendant une op\u00e9ration du cancer. L&rsquo;analyse rapide standard, appel\u00e9e examen extemporan\u00e9, prend g\u00e9n\u00e9ralement de 20 \u00e0 40 minutes, pendant lesquelles le patient reste sous anesth\u00e9sie. PolaOne produit une cartographie de l&rsquo;\u00e9chantillon frais entier en environ 60 secondes, sans colorant et sans ab\u00eemer le tissu, qui peut ensuite suivre l&rsquo;analyse habituelle. Il est d\u00e9j\u00e0 utilis\u00e9 \u00e0 des fins de recherche dans plusieurs laboratoires de pathologie pour collecter les donn\u00e9es de sa validation clinique. Le pr\u00eat financera le marquage CE, vis\u00e9 pour d\u00e9but 2027, et la pr\u00e9paration des premi\u00e8res installations en h\u00f4pital.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Swiss Soil : une surveillance continue des vignes<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.swisssoil.com\/\">Swiss Soil<\/a> g\u00e8re des vignobles pour le compte de viticulteurs avec AGROSTASIS, un syst\u00e8me qui combine analyses du sol et de la s\u00e8ve, donn\u00e9es m\u00e9t\u00e9o et images d&rsquo;un microscope automatis\u00e9 pour \u00e9valuer l&rsquo;\u00e9tat du sol et de la vigne, rep\u00e9rer les signes de stress ou de carence et indiquer o\u00f9 pr\u00e9lever et intervenir. Ses trois composants principaux sont op\u00e9rationnels et ont \u00e9t\u00e9 d\u00e9velopp\u00e9s avec la HEIG-VD, l&rsquo;ETH Zurich et d&rsquo;autres partenaires. En juillet 2026, Innosuisse a approuv\u00e9 un projet de deux ans avec l&rsquo;<a href=\"https:\/\/www.changins.ch\/\">\u00c9cole de viticulture de Changins<\/a> pour tester le syst\u00e8me complet dans des vignobles en 2027 et 2028. Swiss Soil a d\u00e9j\u00e0 sign\u00e9 dix lettres d&rsquo;intention et vise un lancement commercial en 2028. Le pr\u00eat financera sa contribution de CHF 66&rsquo;000 au projet Innosuisse et sa constitution en soci\u00e9t\u00e9 anonyme en vue d&rsquo;un premier tour de financement, et il d\u00e9bloque CHF 100&rsquo;000 de soutien accord\u00e9 par le canton de Vaud.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Fondation pour l&rsquo;Innovation et la Technologie (FIT) soutient trois start-ups actives dans un traitement contre l&rsquo;ost\u00e9oporose, l&rsquo;analyse plus rapide des tissus pendant une chirurgie du cancer et la surveillance de la vigne.<\/p>\n","protected":false},"author":6,"featured_media":40194,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[845],"tags":[1148,1188,1142],"class_list":["post-40197","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech","tag-financing-fr-2","tag-healthcare-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trois start-ups re\u00e7oivent un pr\u00eat Tech Seed de la FIT | GGBa<\/title>\n<meta name=\"description\" content=\"Biodelphis Therapeutics, PolaSight et Swiss Soil re\u00e7oivent chacune CHF 100&#039;000 de la Fondation pour l&#039;Innovation et la Technologie.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trois start-ups re\u00e7oivent un pr\u00eat Tech Seed de la FIT | GGBa\" \/>\n<meta property=\"og:description\" content=\"Biodelphis Therapeutics, PolaSight et Swiss Soil re\u00e7oivent chacune CHF 100&#039;000 de la Fondation pour l&#039;Innovation et la Technologie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T09:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/FIT-PolaSight-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Biodelphis Therapeutics, PolaSight et Swiss Soil obtiennent chacune un pr\u00eat Tech Seed de CHF 100&rsquo;000\",\"datePublished\":\"2026-11-02T09:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/\"},\"wordCount\":543,\"image\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/FIT-PolaSight-1180x811-1.png\",\"keywords\":[\"Financing\",\"Healthcare\",\"R&amp;D\"],\"articleSection\":[\"Tech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/\",\"name\":\"Trois start-ups re\u00e7oivent un pr\u00eat Tech Seed de la FIT | GGBa\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/FIT-PolaSight-1180x811-1.png\",\"datePublished\":\"2026-11-02T09:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Biodelphis Therapeutics, PolaSight et Swiss Soil re\u00e7oivent chacune CHF 100'000 de la Fondation pour l'Innovation et la Technologie.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/FIT-PolaSight-1180x811-1.png\",\"contentUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/FIT-PolaSight-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"Biodelphis Therapeutics, PolaSight et Swiss Soil re\u00e7oivent chacune un pr\u00eat Tech Seed de la FIT. | \u00a9 FIT\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/en\\\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biodelphis Therapeutics, PolaSight et Swiss Soil obtiennent chacune un pr\u00eat Tech Seed de CHF 100&#8217;000\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/author\\\/pierre-yves-oehrli\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trois start-ups re\u00e7oivent un pr\u00eat Tech Seed de la FIT | GGBa","description":"Biodelphis Therapeutics, PolaSight et Swiss Soil re\u00e7oivent chacune CHF 100'000 de la Fondation pour l'Innovation et la Technologie.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/","og_locale":"fr_FR","og_type":"article","og_title":"Trois start-ups re\u00e7oivent un pr\u00eat Tech Seed de la FIT | GGBa","og_description":"Biodelphis Therapeutics, PolaSight et Swiss Soil re\u00e7oivent chacune CHF 100'000 de la Fondation pour l'Innovation et la Technologie.","og_url":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-11-02T09:00:00+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/FIT-PolaSight-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Biodelphis Therapeutics, PolaSight et Swiss Soil obtiennent chacune un pr\u00eat Tech Seed de CHF 100&rsquo;000","datePublished":"2026-11-02T09:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/"},"wordCount":543,"image":{"@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/FIT-PolaSight-1180x811-1.png","keywords":["Financing","Healthcare","R&amp;D"],"articleSection":["Tech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/","url":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/","name":"Trois start-ups re\u00e7oivent un pr\u00eat Tech Seed de la FIT | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/FIT-PolaSight-1180x811-1.png","datePublished":"2026-11-02T09:00:00+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Biodelphis Therapeutics, PolaSight et Swiss Soil re\u00e7oivent chacune CHF 100'000 de la Fondation pour l'Innovation et la Technologie.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/FIT-PolaSight-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/FIT-PolaSight-1180x811-1.png","width":1180,"height":811,"caption":"Biodelphis Therapeutics, PolaSight et Swiss Soil re\u00e7oivent chacune un pr\u00eat Tech Seed de la FIT. | \u00a9 FIT"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/biodelphis-therapeutics-polasight-and-swiss-soil-each-receive-a-chf-100000-tech-seed-loan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Biodelphis Therapeutics, PolaSight et Swiss Soil obtiennent chacune un pr\u00eat Tech Seed de CHF 100&#8217;000"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=40197"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40197\/revisions"}],"predecessor-version":[{"id":40199,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40197\/revisions\/40199"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/40194"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=40197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=40197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=40197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}